Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeline SCHEMBL8305826 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL290804 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL290803 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL14029403 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL13900378 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL2905547 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL467021 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL8994428 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL4264391 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL467022 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113496-A1 | PIPERIDINE MODULATORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113496-A1 | PIPERIDINE MODULATORS OF VMAT2 | OPRM1, OPRD1, OPRL1 | CYP2D6 2665/4885CYP1A2 1965/4885TSHR 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.